Novartis' Hep C Patents Invalid Under Alice, AbbVie Says
AbbVie Inc. is looking to invalidate a suite of Novartis patents, arguing Friday in California that its Swiss rival is collecting licensing fees on the genetic makeup of the Hepatitis C...To view the full article, register now.
Already a subscriber? Click here to view full article